Exchange Traded Concepts LLC Has $607,000 Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Exchange Traded Concepts LLC lifted its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 6.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,403 shares of the life sciences company’s stock after purchasing an additional 2,036 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Integra LifeSciences were worth $607,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Capital Research Global Investors raised its stake in shares of Integra LifeSciences by 37.7% during the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after acquiring an additional 1,621,655 shares during the last quarter. Cooke & Bieler LP increased its holdings in Integra LifeSciences by 12.4% in the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock worth $102,406,000 after purchasing an additional 388,710 shares in the last quarter. Champlain Investment Partners LLC boosted its holdings in shares of Integra LifeSciences by 10.3% during the 1st quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock worth $95,289,000 after buying an additional 252,015 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Integra LifeSciences by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock worth $52,014,000 after purchasing an additional 12,766 shares during the period. Finally, D. E. Shaw & Co. Inc. increased its position in Integra LifeSciences by 64.6% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after buying an additional 335,557 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IART. Morgan Stanley lifted their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Truist Financial cut their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. JMP Securities lowered their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Finally, Bank of America lowered their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $26.50.

Integra LifeSciences Stock Up 0.6 %

IART stock opened at $19.87 on Friday. The stock has a 50-day simple moving average of $19.03 and a two-hundred day simple moving average of $25.57. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $45.42. The firm has a market capitalization of $1.57 billion, a PE ratio of 39.74, a PEG ratio of 0.62 and a beta of 1.09. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same quarter in the prior year, the firm posted $0.71 EPS. Integra LifeSciences’s revenue was up 9.7% on a year-over-year basis. On average, equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.